What is the recommended treatment for acute cellulitis in an adult?

Treatment of Acute Cellulitis in Adults

For outpatient adults with typical nonpurulent cellulitis (no drainage, no abscess), start empiric therapy targeting β-hemolytic streptococci with a β-lactam antibiotic such as cephalexin or amoxicillin for 5-10 days. 1, 2, 3

Clinical Classification and Treatment Algorithm

Step 1: Determine Cellulitis Type

Nonpurulent cellulitis (most common): Erythema, warmth, swelling, tenderness WITHOUT purulent drainage or drainable abscess

• Primary pathogens: β-hemolytic streptococci (Group A Streptococcus), methicillin-sensitive S. aureus 4

Purulent cellulitis: Cellulitis WITH purulent drainage or exudate but no drainable abscess

• Primary pathogen: Community-acquired MRSA (CA-MRSA) 1, 2

Step 2: Assess Severity

Mild (outpatient): No systemic signs, stable vital signs, no altered mental status 3

Moderate: Systemic signs present (fever, tachycardia), but hemodynamically stable 3

Severe: SIRS criteria, hemodynamic instability, rapid progression, extensive disease, immunocompromised, or penetrating trauma 1, 3

Outpatient Treatment Recommendations

For Nonpurulent Cellulitis (Typical Cases)

First-line therapy:

• Cephalexin 500 mg PO every 6-8 hours 3
• Amoxicillin (alternative β-lactam) 1, 2
• Duration: 5 days minimum, extend if not improved 3, 5

The 2014 IDSA guidelines 3 emphasize that empiric MRSA coverage is generally not necessary for typical nonpurulent cellulitis. A 2022 review 4 confirms that despite rising CA-MRSA rates, β-hemolytic streptococci remain the predominant pathogen in nonpurulent cellulitis.

When to add MRSA coverage:

• No clinical response to β-lactam therapy after 48-72 hours 1, 2
• Systemic toxicity present 1
• Risk factors: penetrating trauma, known MRSA colonization, injection drug use, or SIRS 3

For Purulent Cellulitis (Without Drainable Abscess)

Empiric MRSA coverage required:

• Trimethoprim-sulfamethoxazole (TMP-SMX) 1-2 DS tablets PO twice daily 1, 2
• Doxycycline or minocycline 1, 2
• Clindamycin 300-450 mg PO three times daily 1, 2

A 2010 study from Hawaii 6 demonstrated TMP-SMX had significantly higher success rates than cephalexin (91% vs 74%, p<0.001) in areas with high CA-MRSA prevalence (62% of positive cultures).

If dual coverage needed (streptococci + MRSA):

• Clindamycin alone (covers both) 1, 2
• TMP-SMX or tetracycline PLUS amoxicillin 1, 2
• Linezolid alone 1, 2

Inpatient Treatment for Severe Cellulitis

For hospitalized patients with complicated cellulitis:

• IV vancomycin (first-line for MRSA coverage) 1, 2, 3
• Linezolid 600 mg IV/PO twice daily 1, 2, 3
• Daptomycin 4 mg/kg IV once daily 1, 2, 3
• Duration: 7-14 days based on clinical response 1, 2

For nonpurulent cellulitis in hospitalized patients, cefazolin may be considered initially, switching to MRSA-active therapy if no response 1, 2, 3. A 2025 study 7 suggests cefazolin 3g dosing for patients ≥120 kg may improve outcomes.

Treatment Duration

5 days is adequate for uncomplicated cases that show improvement, but extend if infection persists 3, 5. A 2004 randomized trial 5 demonstrated equal efficacy between 5-day and 10-day levofloxacin courses (98% success in both groups) for uncomplicated cellulitis.

Adjunctive Measures

Essential non-pharmacologic interventions:

• Elevation of affected extremity 3
• Examine interdigital toe spaces for tinea pedis—treat fissuring/maceration to reduce recurrence 3
• Address predisposing factors: venous insufficiency, lymphedema, obesity, eczema 3, 8

Consider systemic corticosteroids (prednisone 40 mg daily for 7 days) in nondiabetic adults, though evidence is limited 3. A 2024 meta-analysis 9 found oral NSAIDs as adjunct therapy improved early clinical response at day 3 (RR 1.81,95%CI 1.42-2.31) but not beyond day 5.

Common Pitfalls

Avoid:

• Rifampin as monotherapy or adjunctive therapy 1, 2
• Routine MRSA coverage for typical nonpurulent cellulitis in low-risk patients 3, 4
• TMP-SMX in pregnant women (third trimester) or infants <2 months 2
• Tetracyclines in children <8 years 1, 2

Critical decision point: If patient fails to improve on β-lactam therapy within 48-72 hours, reassess for MRSA, deeper infection, or misdiagnosis (pseudocellulitis mimics like venous stasis dermatitis, contact dermatitis) 3, 4.